Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | SORD | Q00796 | 8/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745658 | 0.85 | NR1H2 (0.34) | NR1H2AOC3SORDCYP2D6HSD17B10 | |
| SCHEMBL20745559 | 0.81 | AOC3 (0.35) | AOC3SCN9AHSD17B10 | |
| SCHEMBL22320566 | 0.77 | ACACB (0.41) | NR1H2SORDDYRK1A | |
| SCHEMBL20745099 | 0.76 | EGFR (0.37) | NR1H2AOC3SORDCYP2D6HSD17B10 | |
| SCHEMBL24921032 | 0.75 | AOC3 (0.39) | AOC3DYRK1ACRBN | |
| SCHEMBL20745663 | 0.74 | SORD (0.41) | NR1H2AOC3SORDDYRK1A | |
| SCHEMBL20745928 | 0.74 | NR1H2 (0.39) | NR1H2AOC3SORDSCN9A | |
| SCHEMBL20745052 | 0.73 | DYRK1A (0.48) | NR1H2SORDCYP2D6HSD17B10DYRK1A | |
| SCHEMBL20745976 | 0.73 | ACACB (0.43) | NR1H2AOC3SORD | |
| SCHEMBL20745044 | 0.72 | NR1H2 (0.36) | NR1H2SORDCYP2D6HSD17B10DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3668504-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | NR1H2 3570/4885AOC3 3230/4885SORD 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.